EMEA-001214-PIP08-21
Key facts
Invented name |
Fasenra
|
Active substance |
Benralizumab
|
Therapeutic area |
Pneumology-allergology
|
Decision number |
P/0497/2021
|
PIP number |
EMEA-001214-PIP08-21
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 855326000 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|